Beta
Alirocumab
medicationPCSK9 inhibitor (brand name: Praluent) - injectable biologic for cholesterol management. Similar effectiveness to Repatha.
Reported Benefits
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of the Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody Alirocumab in Healthy Chinese Subjects
Y. Li, et al.
In 35 healthy Chinese subjects, single doses of 75, 150, or 300 mg alirocumab were safe and well-tolerated, rapidly suppressing free PCSK9 within 4 hours and reducing LDL-C and other lipids consistently with other populations.
A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of the PCSK9 Inhibitor Alirocumab According to Injection Site in Healthy Subjects
R. Dent, et al.
In 60 healthy subjects, a single 75 mg subcutaneous dose of alirocumab into abdomen, upper arm, or thigh reduced LDL-C by 39.5-48.4% at nadir on day 15, suppressed free PCSK9 to near zero by day 3-4, and was well-tolerated with only mild injection site reactions.
Population Pharmacokinetic Analysis of Alirocumab, a Fully Human Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody
R. P. Allaire, et al.
Analysis of data from 2799 subjects including healthy volunteers showed alirocumab follows target-mediated disposition with predictable PK; body weight and statins mildly affect clearance but without clinical significance, accurately modeling exposures in healthy populations.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of the Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody Alirocumab in Healthy Chinese Subjects
Y. Li, et al.
In 35 healthy Chinese subjects, single doses of 75, 150, or 300 mg alirocumab were safe and well-tolerated, rapidly suppressing free PCSK9 within 4 hours and reducing LDL-C and other lipids consistently with other populations.
A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of the PCSK9 Inhibitor Alirocumab According to Injection Site in Healthy Subjects
R. Dent, et al.
In 60 healthy subjects, a single 75 mg subcutaneous dose of alirocumab into abdomen, upper arm, or thigh reduced LDL-C by 39.5-48.4% at nadir on day 15, suppressed free PCSK9 to near zero by day 3-4, and was well-tolerated with only mild injection site reactions.
Population Pharmacokinetic Analysis of Alirocumab, a Fully Human Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody
R. P. Allaire, et al.
Analysis of data from 2799 subjects including healthy volunteers showed alirocumab follows target-mediated disposition with predictable PK; body weight and statins mildly affect clearance but without clinical significance, accurately modeling exposures in healthy populations.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Research (3 studies)
Community updates
No updates yet for this supplement.
Be the first to share your experience!